Union Budget 2026: FM Unveils ‘Biopharma Shakti’ With Rs 10,000 Crore Push To Make India Global Hub
Union Budget 2026 LIVE Updates : Union Finance Minister Nirmala Sitharaman is currently presenting the Union Budget 2026 today (Sunday 1 February 2026) for the upcoming fiscal year beginning 1st April 2026. Among the headline announcements, the biggest boost has come for the healthcare and life sciences sector with a major focus on biopharma manufacturing.
In a landmark move aimed at strengthening India’s position in advanced medicine, the Finance Minister announced: “To develop India as a global bio-pharma manufacturing hub, I propose Bio Pharma Shakti with an outlay of Rs 10,000 crores over the next 5 years. This will build an ecosystem for domestic productions of biologics and biosimilars .”
The Union Budget 2026 proposal signals a decisive shift towards research-led growth. The government proposes to allocate Rs 10,000 crore for the biopharma sector, Finance Minister Nirmala Sitharaman said in her budget speech. India will become a global biopharma hub under ‘ Biopharma Shakti ’ with Rs 10,000 crore outlay over five years. It will create network of 1,000 accredited trial sites to bolster biopharma industry.
Experts believe the Biopharma Shakti mission could transform domestic drug development, reduce dependence on imports and accelerate innovation in vaccines, gene therapy and complex biologics. The creation of accredited trial sites is expected to improve clinical research standards and attract global investment into India’s growing life sciences ecosystem.
Highlighting the broader economic strategy behind the Union Budget 2026, the Finance Minister stressed the pace of structural change. “The government has undertaken comprehensive reforms for accelerating growth, boosting productivity,” she said. “More than 350 reforms have been rolled out recently. The reform express is well on its way.”
Industry leaders have welcomed the announcement, calling it one of the most forward-looking steps in recent years. With rising global demand for affordable biologics, India’s cost advantage and skilled workforce could make the country a preferred destination for biopharma manufacturing.
The Budget 2026 focus on innovation, research infrastructure and regulatory support is expected to generate new jobs, strengthen start-ups and encourage collaboration between academia and private companies. Analysts say the Rs 10,000 crore package under Biopharma Shakti may also help Indian firms compete with established global players in the US and Europe.
In a landmark move aimed at strengthening India’s position in advanced medicine, the Finance Minister announced: “To develop India as a global bio-pharma manufacturing hub, I propose Bio Pharma Shakti with an outlay of Rs 10,000 crores over the next 5 years. This will build an ecosystem for domestic productions of biologics and biosimilars .”
The Union Budget 2026 proposal signals a decisive shift towards research-led growth. The government proposes to allocate Rs 10,000 crore for the biopharma sector, Finance Minister Nirmala Sitharaman said in her budget speech. India will become a global biopharma hub under ‘ Biopharma Shakti ’ with Rs 10,000 crore outlay over five years. It will create network of 1,000 accredited trial sites to bolster biopharma industry.
You may also like
Experts believe the Biopharma Shakti mission could transform domestic drug development, reduce dependence on imports and accelerate innovation in vaccines, gene therapy and complex biologics. The creation of accredited trial sites is expected to improve clinical research standards and attract global investment into India’s growing life sciences ecosystem.
Highlighting the broader economic strategy behind the Union Budget 2026, the Finance Minister stressed the pace of structural change. “The government has undertaken comprehensive reforms for accelerating growth, boosting productivity,” she said. “More than 350 reforms have been rolled out recently. The reform express is well on its way.”
Industry leaders have welcomed the announcement, calling it one of the most forward-looking steps in recent years. With rising global demand for affordable biologics, India’s cost advantage and skilled workforce could make the country a preferred destination for biopharma manufacturing.
The Budget 2026 focus on innovation, research infrastructure and regulatory support is expected to generate new jobs, strengthen start-ups and encourage collaboration between academia and private companies. Analysts say the Rs 10,000 crore package under Biopharma Shakti may also help Indian firms compete with established global players in the US and Europe.
More from our partners
Loving Newspoint? Download the app now
